Miguel Gallardo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4167241/publications.pdf

Version: 2024-02-01

39 papers	602 citations	623188 14 h-index	610482 24 g-index
39 all docs	39 docs citations	39 times ranked	1259 citing authors

#	Article	IF	Citations
1	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. Haematologica, 2021, 106, 2325-2333.	1.7	18
2	Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. Micromachines, 2021, 12, 90.	1.4	5
3	The EÂµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies. Frontiers in Immunology, 2021, 12, 634584.	2.2	3
4	Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma. Cancers, 2021, 13, 1662.	1.7	10
5	Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers, 2021, 13, 3189.	1.7	3
6	Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. Journal of the National Cancer Institute, 2020, 112, 95-106.	3.0	22
7	Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells. Micromachines, 2020, 11, 261.	1.4	5
8	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica, 2019, 104, 288-296.	1.7	36
9	Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness. Blood, 2019, 134, 836-840.	0.6	9
10	GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Frontiers in Immunology, 2019, 10, 2361.	2.2	45
11	A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2019, 62, 6035-6046.	2.9	29
12	PF250 HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA. HemaSphere, 2019, 3, 76-77.	1.2	0
13	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Scientific Reports, 2019, 9, 18630.	1.6	24
14	Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. Haematologica, 2019, 104, 937-946.	1.7	5
15	S846 HNRNP K LEVELS PREDICT FOR POOR CLINICAL RESPONSES IN DLBCL AND REPRESENT A NOVEL THERAPEUTIC TARGET. HemaSphere, 2019, 3, 377-378.	1.2	0
16	PF566 INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY. HemaSphere, 2019, 3, 235-236.	1.2	0
17	PF224ÂNOVEL ICMT INHIBITOR AS POTENTIAL TREATMENT OF RASâ€ÐRIVEN ACUTE MYELOID LEUKEMIA. HemaSphere, 2019, 3, 64-65.	1.2	0
18	PS1357 FITNESS SIGNATURES IN MULTIPLE MYELOMA PROGRESSION AND RESISTANCE. HemaSphere, 2019, 3, 620.	1.2	0

#	Article	IF	Citations
19	Microengineering double layer hydrogel structures towards the recapitulation of the hematopoietic stem cell niche. Science Bulletin, 2018, 63, 1319-1323.	4.3	5
20	hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis. Blood, 2018, 132, 1346-1346.	0.6	0
21	Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL. Blood, 2018, 132, 4416-4416.	0.6	1
22	hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. Blood, 2018, 132, 2622-2622.	0.6	0
23	Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica, 2017, 102, 2048-2057.	1.7	18
24	p53-independent ibrutinib responses in an EÎ¼-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer Journal, 2016, 6, e434-e434.	2.8	10
25	Aberrant hnRNP K expression: All roads lead to cancer. Cell Cycle, 2016, 15, 1552-1557.	1.3	74
26	hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation. Blood, 2016, 128, 744-744.	0.6	3
27	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell, 2015, 28, 486-499.	7.7	110
28	hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. Blood, 2015, 126, 439-439.	0.6	0
29	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Molecular Cancer, 2013, 12, 142.	7.9	20
30	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. British Journal of Haematology, 2013, 161, 667-676.	1.2	20
31	BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The EÎ¼-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. Blood, 2013, 122, 876-876.	0.6	0
32	Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms. Blood, 2012, 120, 5054-5054.	0.6	0
33	Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. Journal of Clinical Pathology, 2011, 64, 1010-1013.	1.0	20
34	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Annals of Hematology, 2011, 90, 939-946.	0.8	7
35	Proteomic Analysis Identifies HSP70 As a Novel Target Therapy to Polycythemia Vera. Blood, 2011, 118, 2827-2827.	0.6	9
36	Metalloproteases Could Be Involved in Erythroid Differenciation in MPN. Blood, 2011, 118, 5161-5161.	0.6	0

#	Article	IF	Citations
37	High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations. Journal of Molecular Diagnostics, 2009, 11, 155-161.	1.2	48
38	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Annals of Hematology, 2008, 87, 741-749.	0.8	43
39	Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age.. Blood, 2007, 110, 4654-4654.	0.6	0